ELDN Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (17 May 2024 @ 16:00):

Stats
Today's Volume	606 607
Average Volume	175 476
Market Cap	73.08M
EPS	$0 ( 2024-05-09 )
Next earnings date	( $-0.390 ) 2024-06-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.840
ATR14	$0.0210 (0.69%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-09	Bvf Partners L P/il	Buy	1 031 385	Common Stock, $0.001 par value
2024-05-09	Bvf Partners L P/il	Buy	3 173 135	Pre-funded Warrants to Purchase Common Stock
2024-05-09	Bvf Partners L P/il	Buy	821 121	Common Stock, $0.001 par value
2024-05-09	Bvf Partners L P/il	Buy	2 526 238	Pre-funded Warrants to Purchase Common Stock
2024-05-09	Bvf Partners L P/il	Buy	232 068	Pre-funded Warrants to Purchase Common Stock

INSIDER POWER
100.00
Last 95 transactions
Buy: 25 564 142 \| Sell: 1 575 675

Volume Correlation

Long: -0.06 (neutral)

Short: -0.04 (neutral)

Signal:(57.724) Neutral

Eledon Pharmaceuticals, Correlation

10 Most Positive Correlations
GLPG	0.883
HAIN	0.848
NSTG	0.845
ONEM	0.844
CLLS	0.841
FREQ	0.833
SOPA	0.832
MLAB	0.825
AIHS	0.825
ONCR	0.823

10 Most Negative Correlations
ACLS	-0.87
RDI	-0.865
INOD	-0.859
RMRM	-0.858
DMAC	-0.851
SPSC	-0.849
IESC	-0.846
CTLP	-0.845
NVTS	-0.844
ALOR	-0.84

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Eledon Pharmaceuticals, Correlation - Currency/Commodity

-0.26
( neutral )

0.20
( neutral )

0.00
( neutral )

-0.24
( neutral )

0.31
( neutral )

Eledon Pharmaceuticals, Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-374 000 (0.00 %)
EPS:	$-1.640

FY	2023
Revenue:	$0
Gross Profit:	$-374 000 (0.00 %)
EPS:	$-1.640

FY	2022
Revenue:	$0
Gross Profit:	$-373 000 (0.00 %)
EPS:	$-6.13

FY	2021
Revenue:	$120 000
Gross Profit:	$120 000 (100.00 %)
EPS:	$-17.31

Financial Reports:

No articles found.

Eledon Pharmaceuticals, Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Eledon Pharmaceuticals,

Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.